ausblenden:
Schlagwörter:
NF-KAPPA-B; ATPASE INHIBITORY FACTOR-1; ISOCITRATE DEHYDROGENASE 1;
CELL-PROLIFERATION; BINDING-PROTEIN; PROMOTER HYPERMETHYLATION; ADJUVANT
TEMOZOLOMIDE; TELOMERE MAINTENANCE; PROGNOSTIC BIOMARKER; CONFERS
RESISTANCECell Biology; Research & Experimental Medicine;
Zusammenfassung:
High-grade adult-type diffuse gliomas are malignant neuroepithelial tumors with poor survival rates in com-bined chemoradiotherapy. The current WHO classification is based on IDH1/2 mutational and 1p/19q code-letion status. Glioma proteome alterations remain undercharacterized despite their promise for a better mo-lecular patient stratification and therapeutic target identification. Here, we use mass spectrometry to characterize 42 formalin-fixed, paraffin-embedded (FFPE) samples from IDH-wild-type (IDHwt) gliomas, IDH-mutant (IDHmut) gliomas with and without 1p/19q codeletion, and non-neoplastic controls. Based on more than 5,500 quantified proteins and 5,000 phosphosites, gliomas separate by IDH1/2 mutational status but not by 1p/19q status. Instead, IDHmut gliomas split into two proteomic subtypes with widespread per-turbations, including aerobic/anaerobic energy metabolism. Validations with three independent glioma pro-teome datasets confirm these subgroups and link the IDHmut subtypes to the established proneural and classic/mesenchymal subtypes in IDHwt glioma. This demonstrates common phenotypic subtypes across the IDH status with potential therapeutic implications for patients with IDHmut gliomas.
